Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
|EU record number
|Company / Sponsor
|Importation of doses of V920 for Emergency Use
|Merck Sharp & Dohme B.V.
|Recombinant Vesicular Stomatitis Virus (rVSV) in which the gene encoding for the VSV glycoprotein G has been deleted and replaced with the gene encoding the Zaire Ebola virus (ZEBOV) glycoprotein (GP).
|Only notified under the "contained use" procedure. Dossier submitted on 24/04/2018.
|A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
|Bavarian Nordic A/S
|Vaccinia virus Ankara strain expression glycoproteins of different RSV strain (MVA-BN)
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2015.
|A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
|Catapult Cell Therapy
|Expression of the Wilms' tumour antigen 1 (WT1)- specific T cell receptor (TCR)